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Abstract
Modulation of the extracellular signal-regulated kinases (ERK-1/2), a signaling pathway directly
associated with cell proliferation, survival, and homeostasis, has been implicated in several
pathologies, including alcoholic liver disease. However, the underlying mechanism of ethanol-
induced ERK-1/2 modulation remains unknown. This investigation explored the effects of ethanol-
associated oxidative stress on constitutive hepatic ERK-1/2 activity and assessed the contribution of
the lipid peroxidation product 4-hydroxynonenal (4-HNE) to the observations made in vivo.
Constitutive ERK-1/2 phosphorylation was suppressed in hepatocytes isolated from rats chronically
consuming ethanol for 45 days. This observation was associated with an increase in 4-HNE-ERK
monomer adduct concentration and a hepatic cellular and lobular redistribution of ERK-1/2 that
correlated with 4-HNE-protein adduct accumulation. Chronic ethanol consumption was also
associated with a decrease in hepatocyte nuclear ELK-1 phosphorylation, independent of changes in
total nuclear ELK-1 protein. Primary hepatocytes treated with concentrations of 4-HNE consistent
with those occurring during oxidative stress displayed a concentration-dependent decrease in
constitutive ERK-1/2 phosphorylation, activity, and nuclear localization that negatively correlated
with 4-HNE-ERK-1/2 monomer adduct accumulation. These data paralleled the decreased
phosphorylation of the downstream kinase ELK-1. Molar ratios of purified ERK-2 to 4-HNE
consistent with pathologic ratios found in vivo resulted in protein monomer-adduct formation across
a range of concentrations. Collectively, these data demonstrate a novel association between ethanol-
induced lipid peroxidation and the inhibition of constitutive ERK-1/2, and suggest an inhibitory
mechanism mediated by the lipid peroxidation product 4-hydroxynonenal.
Oxidative stress and the subsequent formation of reactive oxygen species have been correlated
with a number of disease states in animal models and humans. It is well documented that chronic
ethanol consumption results in hepatic oxidative stress (1,2) causing the peroxidation of
membrane lipids and the production of highly reactive α,β-unsaturated aldehydes (1,3). Recent
evidence suggests that the major lipid peroxidation product 4-hydroxynonenal (4-HNE)2 is
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associated with several hepatic disease states, including alcoholic liver disease (ALD), hepatitis
C, hepatic iron overload, and primary biliary cirrhosis (4).
The production of reactive oxygen species during cellular oxidative stress is thought to be the
key event initiating the autocatalytic degradation of polyunsaturated fatty acids to yield
electrophilic aldehyde species (1). These highly reactive lipid aldehydes are capable of
diffusing from their point of origin to impose diverse effects on more distant cellular
nucleophiles through covalent interactions (5). 4-HNE has been shown to affect a wide range
of biological activities through its ability to react with nucleophiles on proteins and nucleic
acids. In fact, the adduction of proteins by 4-HNE has been demonstrated in vitro using purified
proteins (6), in cell culture (3), and in animal models of chronic ethanol and/or iron overload
(7-9). Additionally, the presence of 4-HNE-protein adducts has been documented in patients
with alcoholic liver disease, hepatitis C, primary biliary cirrhosis, and other chronic liver
diseases (10,11). These data support the presence of 4-HNE-protein adducts as reliable
biomarkers of hepatic lipid peroxidation (12-14) and suggest a direct correlation between lipid
peroxidation and several pathologic states associated with oxidative stress.
The diverse cellular effects of lipid aldehydes result from their diffusible nature and rapid
reactivity. 4-HNE has been shown to preferentially modify cysteine (Cys), histidine (His), and
lysine (Lys) residues via Michael addition and for Lys, Schiff base products (1,15,16). At high
concentrations, 4-HNE is cytotoxic to several cell types (17), whereas micromolar and
submicromolar concentrations of 4-HNE have been shown to induce various nontoxic, cell-
specific effects. In this regard, 4-HNE is capable of the following: 1) stimulating proliferation
and growth in some cell types (18-20) and apoptosis in others (21-23); 2) positively and
negatively regulating cytokines (24,25), kinases (26,27), and transcription factors (28-30); 3)
activating stress signaling pathways (31) and translational activities (32); and 4) inhibiting
intracellular proteolysis and enzyme activities (6,33). Although it has been routinely
demonstrated that chronic ethanol consumption results in the hepatic accumulation of 4-HNE-
modified proteins (3,34-36), even in the early phases of ALD (9), the specific protein targets
of aldehyde modification and the resulting changes in normal liver function remain largely
unknown.
Although limited, in vivo and in vitro evidence suggest that ethanol-induced 4-HNE
modification of hepatocellular proteins results in the inhibition of normal enzyme function
(34-36). Additionally, it has been shown recently, using an animal model of chronic ethanol
consumption, that hepatic extracellular signal-regulated kinase 1 and 2 (ERK-1/2) activity is
suppressed under similar chronic conditions (37,38). These studies led to the hypothesis that
ethanol-induced lipid peroxidation results in the inhibition of constitutive, hepatic ERK-1/2
activity via covalent adduct formation with 4-HNE. This hypothesis is consistent with recent
in vivo and primary cell culture data that demonstrate a correlation between ethanol exposure
and the inhibition of ERK-1/2 in neurological and vascular pathologies (39-41). This evidence
suggests that ethanol-induced oxidative stress and the resulting lipid peroxidation products are
predominantly inhibitory in nature. Consistent with this proposition, a series of combined in
vivo/in vitro studies have demonstrated the adduction and inhibition of hepatic enzymes that
are crucial for normal cell function and homeostasis, namely the cellular repair proteins heat
shock protein-72 (Hsp-72), Hsp-90, and protein-disulfide isomerase (34-36). The anonymity
of the vast number of 4-HNE-modified proteins demonstrated in the livers of ethanol-treated
rats by Carbone et al. (34-36), using two-dimensional gel electrophoresis, suggests that the
attenuating nature of 4-HNE on the constitutive function of other liver enzymes associated
with normal hepatic function and homeostasis requires further investigation.
The extracellular signal-regulated kinases 1 and 2 are members of the mitogen-activated protein
kinase (MAPK) family whose activation results in cell growth, proliferation, and survival
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(42-44). Because ERK-1 and ERK-2 are highly homologous (>83%) and are thought to carry
out similar kinase functions within the cell, they are collectively referred to as ERK-1/2 (44).
It is well documented that chronic ethanol consumption inhibits hepatic regeneration following
partial hepatectomy or chemical-induced liver injury (45,46), implicating the dysregulation of
the hepatic proliferative ERK-1/2 signaling pathway in ethanol-related liver disease. It has
been shown recently that 4-HNE-protein adduct accumulation is an early event in the
progression of ethanol-induced liver injury (9). In this context, the research presented here set
out to characterize the effects of chronic ethanol exposure and ethanol-induced lipid
peroxidation on constitutive ERK-1/2 using a rat model of early ALD.
The results of this study demonstrate that in vivo ethanol-induced lipid peroxidation increased
hepatic 4-HNE-ERK-1/2 monomer adduct formation and decreased constitutive ERK-1/2
phosphorylation and nuclear localization. These data correlated with the cytosolic
accumulation and hepatolobular redistribution of ERK-1/2 that paralleled the cytosolic and
lobular accumulation of 4-HNE-protein adducts. These observations are correlated with an
ethanol-induced decrease in nuclear ELK-1 phosphorylation that was independent of changes
in total ELK-1 in the nucleus. Furthermore, in experiments using primary hepatocyte cultures,
4-HNE was shown to be a potent inhibitor of constitutive ERK-1/2 phosphorylation, activity,
and nuclear localization. These results establish a strong correlation between ethanol-induced
lipid peroxidation and the dysregulation of hepatocellular ERK-1/2, and suggest a novel
inhibitory mechanism of 4-HNE via adduction of inactive ERK-1/2 monomers that results in




The amino acid sequences for extracellular signal-regulated kinase 2 (or Xenopus equivalent,
myelin basic protein kinase) from Mus musculus, Rattus norvegicus, Xenopus laevis, and Homo
sapiens were obtained from NCBI (P63085, P63086, P26696, and P28482, respectively). These
sequences were manually aligned according to the human sequence to determine the extent of
homology and conservation of potential 4-HNE-reactive sites across experimental species,
when compared with the human ERK-2 sequence.
Animal Model
Twenty male Sprague-Dawley rats weighing ~250 g were obtained from Harlan Inc.
(Indianapolis, IN). Ten ethanol-treated rats were fed a nutritionally fortified liquid diet (Dyets,
Inc., Bethlehem, PA) containing 16% protein-derived calories, 45% fat-derived calories, 4%
carbohydrate-derived calories, and 35% ethanol-derived calories. Ten pair-fed control rats
were administered a similar diet containing carbohydrate-derived calories (39%) isocaloric to
the amount of ethanol consumed by the alcohol-treated rats (34,47). The animals received
ethanol or control diets for 45 days, at which time they were subdivided into two groups of
five control and five ethanol-treated rats, and subjected to the following procedures. 1) Group
1 animals were anesthetized, and their livers removed, weighed, and fixed in paraffin for
immunohistochemical and pathological analysis. 2) Group 2 animals were anesthetized, and
their hepatocytes were isolated, using established procedures described elsewhere (3,48), and
resuspended in phosphate-buffered saline (PBS) with protease inhibitors (4 μl/ml; Sigma) for
total cell protein analysis. Prior to euthanization, venous blood was collected from all animals
for serum alanine aminotransferase and ammonia analysis.
Sampey et al. Page 3














Hepatotoxicity resulting from chronic ethanol treatment was determined using appropriate
biochemical assay kits measuring serum alanine aminotransferase activity and ammonia
concentrations as per the manufacturer’s protocol (Sigma).
Histopathology, Immunostaining, and Imaging
Liver samples were routinely processed, and paraffin-embedded sections of the livers were
stained with hematoxylin and eosin (H & E). Immunostaining was carried out as described
elsewhere (49). Primary antibodies specific for 4-HNE-adducted protein epitopes (3), total and
phosphorylated ERK-1/2, total and phosphorylated ELK-1 (Cell-Signaling Technologies,
Beverly, MA), and proliferating cell nuclear antigen (PCNA) (Santa Cruz Biotechnology,
Santa Cruz, CA) were incubated with liver sections at 4 °C overnight at 1:5000-, 1:1000-,
1:1000-, 1:50-, 1:50-, and 1:2500-fold dilutions, respectively. Immunopositive reactions were
detected indirectly with a secondary biotinylated goat anti-rabbit antibody (1:200).
Visualization of primary and secondary antibody interactions was accomplished by using an
avidin/biotinylated horseradish peroxidase kit (Pierce) incorporating 3′,3′-diaminobenzidine
as the chromogen. The absence of positive staining using this procedure in the absence of
primary antibody established the lack of nonspecific staining because of the secondary
antibody. Image-Pro Plus image acquisition and analysis software (Media Cybernetics, Silver
Spring, MD) integrating a Nikon Eclipse TE300 microscope equipped with a digital camera
was used to capture and analyze representative images of the stained serial sections at ×10,
×40, and ×80 magnifications for each animal treatment group.
Primary Cell Culture and Treatment
Primary rat hepatocytes were isolated from naive, lab chow-fed male Sprague-Dawley rats
(Harlan Inc.) using identical procedures as described above and elsewhere (48). The isolated
hepatocytes were resuspended in RPMI 1640 containing penicillin/streptomycin (100 IU/ml
and 100 μg/ml, respectively), and the cells were plated onto extracellular matrix-coated (Sigma)
100-mm tissue culture plates (BD Biosciences) at a concentration of 3.5 million cells/plate.
Adherent hepatocytes were allowed to acclimate to culture conditions at 37 °C, 5% CO2
overnight before treatment with aldehyde. 4-HNE was synthesized immediately prior to cell
treatment as described previously (50). At the start of treatment, media from acclimatized,
primary hepatocytes were removed and replaced with serum-free RPMI 1640 containing 0,
0.01, 0.1, 1.0, 10, and 100 μM 4-HNE for 4 h under normal cell culture conditions, a time point
previously shown to be effective in similar experiments (51). At the end of each treatment, the
primary hepatocytes were liberated from the extracellular matrix-coated plates with ice-cold
PBS, 1 mM EDTA solution, and the cells were resuspended in PBS with protease inhibitor
mixture (PBS/PI).
LDH Cytotoxicity Assay
The cytotoxicity of 4-HNE was determined using the in vitro cytotoxicity assay (Tox-7; Sigma)
according to the manufacturer’s protocol. Cytotoxicity is indirectly quantified as the ratio of
lactate dehydrogenase (LDH) activity in the media (released) over the total cellular LDH
activity. Media and an aliquot of cells were collected at the appropriate time points for each
cell treatment group and used immediately to determine LDH activity. Naive media and PBS/
PI served as negative controls. LDH conversion of NAD to NADH was indirectly measured
using a Spectra Max 190 (Molecular Devices, Sunnyvale, CA) plate reader, and the data were
collected using SOFTmax PRO 4.0. “Relative cytotoxicity” is reported as the ratio of
absorbance corresponding to released LDH activity over the total cellular LDH activity when
compared with untreated cells.
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Cell Harvest and Protein Isolations
Total cell extracts were prepared by sonicating the hepatocyte suspensions four times for 5 s
on ice using a Sonic Dismembrator (Fisher). Cellular debris was removed by centrifugation,
and the total cell extract protein was quantified using a BCA protein assay kit (Pierce). Samples
were diluted to 1 mg/ml and either used immediately for kinase activity assays or mixed with
6× SDS-PAGE loading buffer, heated to 100 °C for 5 min, and separated by SDS-PAGE for
immunoblot analysis. Alternatively, nuclear protein fractions were isolated from cell treatment
groups using a nuclear isolation kit (Active Motif, Inc.) as per the manufacturer’s protocol.
The nuclear protein fractions were quantified and diluted in PBS/PI to a final concentration of
1 mg/ml.
Immunoprecipitation and Immunoblot Analysis
Samples of total cell extracts (250 μg) were diluted in immunoprecipitation buffer (IP buffer:
50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1% Igepal CA630) to a concentration of 1 mg/ml.
Monoclonal antibodies against ERK-1/2 were added to this mixture at a dilution of 1:100 (Cell
Signaling), and the samples were incubated overnight at 4 °C with gentle agitation. At the end
of incubation, 50 μl of protein A/G-Sepharose bead suspension (Santa Cruz Biotechnology)
was added to each sample and gently mixed for 1 h at 4 °C. Samples were centrifuged at 12,000
rpm for 30 s; the supernatant was aspirated, and the beads were washed three times in 1 ml of
IP buffer. The isolated beads were resuspended in 1× SDS-PAGE loading buffer, heated to
100 °C for 5 min, vortexed, and flash-centrifuged, and the supernatants were loaded onto a
12% SDS-polyacrylamide gel for electrophoretic separation.
For immunoblot analysis, immunoprecipitated protein, 15 μg of total cell extract, 7 μg of
nuclear protein, or 250 ng of recombinant protein was denatured at 100 °C for 5 min in 1×
SDS-PAGE loading buffer. Samples were separated on a 12% SDS-polyacrylamide gel for 2
h (Bio-Rad) and transferred to polyvinylidene difluoride membranes as described previously
(52). Membranes were blocked in 5% (w/v) bovine serum albumin in Tris-buffered saline with
0.2% Tween (TBS-T) at room temperature for 45 min. The primary antibodies used were as
follows: rabbit anti-4-HNE-protein adducts (3); antibodies against total and phospho-specific
ERK-1/2, total and phospho-specific ELK-1, and β-actin (Cell Signaling); and rabbit anti-GST-
Ya (Oxford Biomedical Research, Oxford, MI). Horseradish peroxidase-conjugated secondary
antibodies were from Cell Signaling. ECL-Plus (Amersham Biosciences) enhanced
chemiluminescence reagent was used to visualize antibody-reactive protein bands via film and
a STORM 860 (GE Healthcare) and quantified using ImageQuant software (Amersham
Biosciences). Because ethanol and 4-HNE influenced both ERK-1 and ERK-2 to nearly
identical degrees, densitometry analyses for immunoblots were conducted on the combined
ERK-1/2 bands.
ERK-1/2 Activity Assay
To determine the effects of chronic ethanol ingestion and 4-HNE exposure on ERK-1/2 activity
toward its substrate Ets-like protein 1 (ELK-1), a nonradioactive kinase assay was used as
described elsewhere (53). Monoclonal antibodies raised against phospho-ERK-1/2 conjugated
to agarose beads were used to immunoprecipitate (IP) ERK-1/2 from 250 μg of total hepatocyte
extracts from control and ethanol-treated animals or aldehyde-treated primary cultures. The
immunopurified proteins were incubated with an ELK-1 fusion protein (2 μg/reaction) in the
presence of 200 μM ATP for 30 min at 37 °C. Alternatively, ERK-1/2 immunopurified from
control hepatocytes was incubated with increasing concentrations of 4-HNE, repurified to
eliminate excess 4-HNE, and subjected to the kinase activity assay. The reaction was stopped
by addition of 6× SDS-PAGE loading buffer, incubated at 100 °C for 5 min, vortexed, and
centrifuged at room temperature. Immunoblot against phospho-ELK-1 was used to determine
the ability of immunoprecipitated ERK to phosphorylate ELK-1 fusion protein. 4-HNE-
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ERK-1/2 adducts were determined using identical blots probed with antibodies raised against
4-HNE-protein adducts.
In Vitro Modification of ERK-2 by 4-HNE
Molar ratios of ERK/4-HNE were calculated to mimic in vivo conditions of oxidative stress
according to the literature (1,54). Mouse recombinant ERK-2 (250 ng, 0.2 μM) was incubated
in the presence of 0, 0.01, 0.10, 1.00, 10.0, or 100 μM 4-HNE in 50 mM sodium phosphate buffer,
pH 7.4, for 4 h at 37 °C, corresponding to 4-HNE/ERK-2 molar ratios of 0.05:1, 0.5:1, 5:1,
50:1, and 500:1, respectively. The reactions were stopped by the addition of 6× SDS-PAGE
loading buffer, mixed thoroughly, and incubated at 100 °C for 5 min for immunoblot analysis.
Statistical Analysis
The numerical data associated with each blot are presented as relative abundance and
normalized to that of control, which was given a value of 1. Comparisons were made between
control and ethanol-treated animals or between control and 4-HNE-treated primary cultures
and presented as fold increase from control values. The data are presented as the mean ± S.E.
(n ≥ 3). Where applicable, statistically significant differences between ethanol-treated and pair-
fed controls were determined using the paired t test, and differences between control and 4-
HNE-treated cells were determined using the Student’s t test feature of SigmaPlot 6.0 (SPSS
Inc., Chicago, IL). Statistical significance was set at p < 0.05.
RESULTS
Sequence Analysis of ERK-2
Amino acid sequence alignment of ERK-2 (or the ERK-2 homologue, myelin basic protein
kinase) from H. sapiens, M. musculus, R. norvegicus, and X. laevis revealed a highly conserved
core region across these species that was >96.5% identical to the human sequence (Fig. 1).
Because 4-HNE preferentially modifies Cys, His, and Lys residues (15), these sequences were
evaluated to establish the conservation of these target sites for each species of ERK-2 when
compared with human. The total number of residues for human, mouse, rat, and Xenopus
ERK-2 that are potential targets for 4-HNE modification are 43, 43, 43, and 45 per protein
monomer, respectively (Table 1). As expected from the sequence alignment, these sites were
also highly conserved. These results support the use of experimental variants of ERK-1/2 as
appropriate alternatives to the human form.
Chronic Ethanol Administration Results in 4-HNE Modification of Hepatic ERK-1/2 and
Suppression of ERK-1/2 Phosphorylation
Oxidative stress, lipid peroxidation, and 4-HNE production has been shown in patients
associated with both acute and chronic ethanol consumption (55). Because we are interested
in initiation and sensitizing events in ALD, a rat model of early ALD (34-36) utilizing a
modified Lieber-De-Carli diet to produce blood-ethanol concentrations, lipid peroxidation, and
pathologic liver changes consistent with early ALD in humans (56) was used to determine the
ethanol-induced effects of chronic alcohol consumption on constitutive, hepatic ERK-1/2
activity and localization. Table 2 demonstrates that this model of ALD results in a moderate
but significant increase in serum alanine aminotransferase and ammonia levels and liver to
body weight ratios over control, indicative of mild liver damage. Consistent with the data in
Table 2, the results in Fig. 2, B and B2, reveal the loss of normal liver structure associated with
the accumulation of lipid in hepatocytes following chronic ethanol ingestion, when compared
with control livers (Fig. 2A). The pathology associated with ethanol consumption in this study
was limited to steatosis and lacked indices of progressive ALD, such as inflammation and/or
necrotic foci. Although diffuse, pan-lobular staining for 4-HNE-adducts occurs in control livers
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(Fig. 2C), the chronic administration of alcohol resulted in the pronounced accumulation of 4-
HNE-modified proteins that are most prominent in the mid-zonal and periportal regions of the
lobule and conspicuously absent in the pericentral zones (Fig. 2D). Under higher magnification
(Fig. 2D2, ×80) prominent cytosolic accumulation of proteinaldehyde adducts is apparent,
indicating a cellular compartmentalization in addition to the lobular patterning observed at the
×10 magnification. Similar to the distribution of 4-HNE-protein adducts observed in Fig. 2C,
Fig. 2E shows a mild, diffuse immunopositive staining for total ERK-1/2 in the livers of control
animals that is pan-lobular in distribution. Surprisingly, the lobular localization of ERK-1/2 is
redistributed resultant to prolonged ethanol exposure (Fig. 2F) in a manner that follows 4-
HNE-protein adduct accumulation (Fig. 2D), demonstrating a prominent cytosolic
accumulation (Fig. 2F2) in the midzonal and periportal regions, yet lacking in the centrilobular
zones. Using antibodies against total ERK-1/2, ×40 magnification reveals that chronic ethanol
treatment results in a 2.39 ± 0.06-fold decrease in positive staining hepatocyte nuclei (Fig.
2F2; n = 7, p < 0.0001) that was paralleled by a 2.59 ± 0.06-fold decrease in phospho-ERK-1/2
positive staining hepatocyte nuclei (Fig. 2H) when compared with control numbers (Fig. 2G;
n = 13, p < 0.0001). Although the number of positive staining nuclei (per ×40 field) decrease
for total and phospho-ERK-1/2 from control to ethanol groups, the ratio of positive phospho-
ERK/Total-ERK nuclei is unchanged between the two groups, with control ratios of 1.01 ±
0.08 and ethanol ratios of 0.93 ± 0.12, indicating ERK-1/2 phosphorylation and nuclear
localization are directly correlated in this model. Although the pattern of staining that was
observed in the ethanol-treated group using anti-4-HNE and anti-total ERK-1/2 antibodies was
inconspicuous under low magnification when liver sections were stained against total and
phospho-ELK-1, under high magnification there is a 2.63 ± 0.23-fold decrease in the number
of hepatocyte nuclei staining positive for phosphorylated ELK-1 (per ×40 field) when ethanol
groups are compared with control (Fig. 2, L and K, respectively; n = 9, p < 0.0004). This effect
is independent of significant changes between control and ethanol groups in the number of
hepatocyte nuclei per ×40 field staining positive for total ELK-1 (Fig. 2, I and J; control =
50.71 ± 3.94, ethanol = 52.00 ± 6.99, p = 0.8757). Accordingly, the ratio of phospho-ELK-1/
total-ELK-1 decreases from 0.93 ± 0.10 in control livers to 0.34 ± 0.10 in ethanol livers,
demonstrating dissociation between ELK-1 phosphorylation and nuclear localization in the
liver under the conditions described here. These data indicate a close correlation between
hepatic lipid peroxidation and ERK-1/2 cytosolic accumulation in the liver following chronic
ethanol exposure in vivo, which results in the loss of constitutive signal transduction to the
nuclear ELK-1 substrate.
Immunoblot analysis was used to examine the consequences of chronic ethanol consumption
on ERK-1/2 in total hepatocyte extracts from control and ethanol-treated animals. The data
presented in Fig. 3A shows that no changes in total ERK-1/2 protein concentrations are
observed in hepatocytes of ethanol-treated animals when compared with pair-fed controls.
However, Fig. 3B demonstrates that chronic ethanol administration resulted in the ablation of
constitutive ERK-1/2 phosphorylation. To evaluate the potential interactions of the lipid
peroxidation product 4-HNE and ERK-1/2, ERK-2 was immunoprecipitated from hepatocyte
extracts of control and ethanol-treated animals, and the extent of 4-HNE modification was
determined using immunoblot analysis. Fig. 3C illustrates that chronic ethanol exposure
significantly increased the amount of 4-HNE-ERK-2 protein monomer adducts in hepatocytes
when compared with control animals (1.735-fold, ±0.295), which became increasingly greater
when normalized to the total ERK protein immunoprecipitated (Fig. 3D, from p < 0.0244 to
p < 0.0041). Fig. 3D shows the immunopurified ERK-2 band as a Coomassie-stained 42-kDa
protein within the polyacrylamide gel, indicating a slightly greater amount of ERK-2 isolated
from control animals when compared with ethanol-treated animals. The significant differences
observed between the ethanol-treated groups for total ERK-1/2 immunoblot (Fig. 3A) and the
immunoprecipitated ERK-2 (Fig. 3D) are likely due to differences in the polyclonal and
monoclonal antibodies used, respectively. Collectively, these data suggest a mechanistic
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association between ethanol-induced lipid peroxidation and the inhibition of constitutive
ERK-1/2 activity in the liver, and allude to the cytosolic accumulation of inactive 4-HNE-
ERK-1/2 monomers.
4-HNE Modulates ERK-1/2 Activity in Isolated Hepatocytes
To determine the effects of 4-HNE on ERK-1/2 signaling, primary rat hepatocyte cultures were
exposed to concentrations of 4-HNE commonly associated with pro-oxidant-induced lipid
peroxidation (57). To ensure that the effects of 4-HNE on ERK-1/2 signaling were not
associated with cytotoxic hepatocyte responses to exogenous 4-HNE, cytotoxicity of 4-HNE
over a range of physiologic concentrations was evaluated as the ratio of released LDH activity
over total cellular LDH activity (Fig. 4A). These data show that, when compared with untreated
controls (no cytotoxicity), 4-HNE concentrations ranging from 0.01 to 100 μM did not result in
any significant cytotoxicity. Only at 1000 μM 4-HNE did a dramatic and significant increase in
cytotoxicity occur, as determined by a 20-fold increase in LDH activity ratio (p < 0.0001). For
subsequent experiments, nontoxic concentrations of 0.01–100 μM 4-HNE were used to
investigate the effects of exogenous 4-HNE on hepatocyte ERK-1/2 signaling.
To evaluate the contribution of 4-HNE to the altered hepatic ERK phosphorylation state
observed in vivo, primary rat hepatocyte cultures were exposed to subtoxic concentrations of
4-HNE over a 4-h period. Similar to the data from chronic ethanol treatment in vivo (Fig.
3A), the immunoblot and densitometry in Fig. 4B reveal that 4-HNE treatment of primary
hepatocytes across a broad range of physiologic concentrations does not result in changes in
total ERK-1/2 protein concentrations in total hepatocyte extracts. However, Fig. 4C illustrates
a representative immunoblot with corresponding densitometry analysis for phosphorylated
ERK-1/2 using total cell extracts from identical cells treated for 4 h with 0.00–100.0 μM 4-HNE.
These data show that treatment of primary hepatocytes with 4-HNE leads to a marked
concentration-dependent decrease in constitutive ERK-1/2 phosphorylation (50% at 100 μM),
which becomes significant at aldehyde concentrations of 0.10 μM.
A nonradioactive IP kinase activity assay was used to determine whether 4-HNE-mediated
inhibition of ERK-1/2 phosphorylation (Fig. 4C) results in a correlative decrease in ERK-1/2
activity toward its substrate ELK-1. Initially, IP-phospho-ERK-1/2 from control hepatocytes
was incubated with increasing concentrations of 4-HNE prior to analysis via kinase activity
assay. Surprisingly, the immunoblot shown in the inset of Fig. 4D reveals that 4-HNE is
incapable of affecting the activity of phosphorylated, active ERK-1/2 toward an ELK-1 fusion
protein. Conversely, the immunoblot and densitometry in Fig. 4D represent the ability of IP-
ERK-1/2 from cells treated with increasing concentrations of 4-HNE to phosphorylate ELK-1
fusion protein. Densitometry analysis of these data demonstrates that the decrease in ERK-1/2
phosphorylation (Fig. 4C) correlates with a loss in ERK-1/2 kinase activity (Fig. 4D) and
indicates that 4-HNE affects ERK-1/2 prior to activation in the cell. To establish that 4-HNE
modification of ERK-1/2 was associated with the observed loss of ERK-1/2 activity, ERK-1/2
immunoprecipitated from hepatocytes exposed to increasing concentrations of 4-HNE was
probed with the antibodies specific for 4-HNE-protein adducts. Fig. 4E demonstrates a
significant concentration-dependent increase in adduct formation with aldehyde exposure that
correlates with the loss of ERK-1/2 phosphorylation and activity shown in Fig. 4, C and D,
respectively. These results show that in primary hepatocytes, the decrease in ERK-1/2
phosphorylation and activity resulting from increased 4-HNE treatment inversely correlate
with the level of 4-HNE-ERK-1/2 monomer adduct concentration, which is consistent with
observations made in vivo (Fig. 3, B and C).
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4-HNE Attenuates Nuclear Concentrations of Total and Phospho-ERK-1/2 and Phospho-
ELK-1
The activation of ERK-1/2 has been shown to affect various transcriptional and translational
activities; however, the nuclear localization of ERK-1/2 is largely responsible for the
transcriptional effects mediated by ELK-1 (42,53,58). Although the 4-HNE responses
described above establish the aldehyde-mediated modulation of ERK-1/2 activation, it was
important to determine whether these results parallel the modulation of active, nuclear
ERK-1/2. The 4-HNE effects on ERK-1/2-mediated transcription were explored by comparing
the activation state of nuclear ERK-1/2 with the cellular observations previously mentioned
(Fig. 4, C and D) using primary hepatocytes treated with aldehyde as before. Nuclear proteins
were subjected to SDS-PAGE separation and immunoblot analysis using antibodies against
total or phospho-specific ERK-1/2. The purity of nuclear proteins was determined by the
absence of positive band staining on these nuclear blots when stripped and re-probed for the
cytosolic marker GST-Ya (data not shown). Contrary to the studies using total cell extracts
(Fig. 4, B and C), Fig. 5A shows a representative immunoblot, and corresponding densitometry
analysis demonstrating incubation of hepatocytes with increasing 4-HNE leads to a
concentration-dependent decrease in total nuclear ERK-1/2 concentrations, which are similar
to ethanol-induced observations made in vivo (Fig. 2, E and F2). These results are associated
with a corresponding decrease in phosphorylated, nuclear ERK-1/2, as demonstrated in Fig.
5B, which also correlate with ethanol-induced effects observed in the rat liver (Fig. 2, G and
H). Because double phosphorylation and activation of ERK-1/2 are required for nuclear
localization (44), these data indicate that adduction and inhibition via 4-HNE occur in the
cytosolic compartment, resulting in the cytosolic accumulation of inactive, unphosphorylated
4-HNE-ERK-1/2 adducts.
Immunoblot analysis of nuclear protein fractions from aldehyde-treated cells was used to
determine the activity of nuclear ERK-1/2, by blotting against the ERK-1/2 substrate ELK-1.
Fig. 5C shows that the concentration of total nuclear ELK-1 is unaffected by increasing
concentrations of 4-HNE, an observation consistent with ethanol-related effects on total
nuclear ELK-1 observed in vivo (Fig. 2, I and J). However, like the rat studies (Fig. 2, K and
L), the phosphorylation state of nuclear ELK-1 decreases with increasing 4-HNE
concentrations, which is indicative of a concentration-dependent loss of ERK-1/2 activity in
the nucleus (Fig. 5D). These data further support the cytosolic adduction and inhibition of
ERK-1/2, which renders the kinase pathway impotent toward the intermediate kinase and
transcription factor ELK-1.
In Vitro Modification of ERK-2 by 4-HNE
Because the evidence presented above suggests 4-HNE inhibits ERK-1/2 by forming adducts
with the inactive, unphosphorylated ERK monomers, in vitro conditions were defined to test
this hypothesis. Purified, recombinant ERK-2 from M. musculus (Cell Signaling) was
incubated with concentrations of 4-HNE ranging from 0.01 to 100 μM, simulating molar ratios
present during mild to marked oxidative stress. Fig. 6A is a representative immunoblot
demonstrating 4-HNE-ERK-2 adducts using antibodies raised against 4-HNE-modified protein
epitopes (3). This image indicates that stable adducts are formed at 42 kDa over 1–100 μM 4-
HNE (5:1–500:1 molar ratios of 4-HNE to ERK-2). At the highest concentration evaluated, 4-
HNE forms adducts resulting in cross-linked ERK-2 monomers as indicated by a partial band
shift from 42-kDa at 1–100 μM 4-HNE to ~84 and 126-kDa at 100 μM 4-HNE (Fig. 6A,
arrowheads). Concurrent with the formation of 4-HNE-ERK-2 cross-links, Fig. 6B shows a
loss of a positive signal at 100 μM 4-HNE that occurs using identical blots probed for total
ERK-1/2. This is likely due to the masking of epitopes that results from the formation of cross-
linked monomers and/or the adduction of a different residue than that which results in monomer
adducts. These experiments confirm that 4-HNE is capable of forming covalent adducts with
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inactive ERK protein monomers at molar ratios consistent with the formation of 4-HNE-
ERK-1/2 monomer adducts observed in vivo following chronic ethanol exposure, and in
primary cultures exposed to aldehyde. Because our rat model of early ALD and the subsequent
primary hepatocyte experiments yield only the monomer adduct species, it appears that the
formation of 4-HNE-ERK monomer adducts is responsible for the loss of ERK-1/2
phosphorylation and activity observed in the studies described here.
DISCUSSION
4-HNE is the prototypic toxic end product of lipid peroxidation that results from oxidative
stress (1), and lipid-aldehydes like 4-HNE are thought to be the major bioactive molecules that
mediate the pathomechanisms associated with chronic alcoholic liver disease (3,10,11,16,
34-36,52,54,59,60). Although this notion permeates a broad range of disease research,
insufficient data are available to explain the mechanisms fundamental to 4-HNE-mediated
disease progression in vivo. The present studies indicate that hepatic 4-HNE-protein adducts
co-localize with ERK-1/2 following chronic ethanol consumption at the cellular and
hepatolobular levels, and they demonstrate an increase in ethanol-induced 4-HNE-ERK-1/2
adduct concentration that inversely correlates with a loss of constitutive ERK-1/2
phosphorylation and nuclear localization in hepatocytes from ethanol-treated animals. These
results are supported by observations showing a concentration-dependent decrease in ERK-1/2
phosphorylation, activity, and nuclear localization in primary hepatocytes following 4-HNE
treatment. This mode of action by 4-HNE on ERK-1/2 activity is consistent with recent reports
that demonstrate decreased phosphorylation of ERK-1/2 associated with neurological and
vascular manifestations of chronic ethanol exposure in in vivo and primary culture (39-41),
and the loss of hepatic ERK-1/2 sensitivity to chemical activation (ex vivo) following chronic
ethanol ingestion (61). Although these published studies fail to demonstrate a specific
mechanism of inhibition, ethanol-induced oxidative stress and lipid peroxidation have been
demonstrated in hepatic and extra-hepatic tissues (62).
Because lipid peroxidation and the presence of 4-hydroxynonenal has been demonstrated
within the liver using experimental models of ALD (9,57,63,64) and clinically in human
alcoholics (10,11), it is facile to hypothesize that 4-HNE is involved in the dynamic evolution
of ALD. Although there are many factors that converge to dictate the onset and severity of the
pathogenesis related to ALD, the identification of 4-HNE as the most abundant and cytotoxic
of the aldehydes resulting from lipid peroxidation indicates its importance in the etiology of
the disease (65). In addition to the formation of reactive aldehydes through lipid peroxidation,
ALD is also associated with the subsequent formation of covalent aldehyde-protein adducts
(66-69). It is well known that ERK-1/2 is linked with cellular homeostasis in differentiated
cells, such as hepatocytes (42,44). In this study, the adduction of ERK monomers and
corresponding inhibition of constitutive ERK-1/2 activity in hepatocytes in vivo and in primary
culture represent a novel mechanism for ethanol-induced homeostatic imbalance in the liver
that is mediated by 4-HNE. It is important to emphasize, given the nature of the early model
of ALD used in this study, that these changes in normal ERK-1/2 signaling represent potential
initiating and/or sensitizing mechanisms that are early events in the development of ALD.
Recent research demonstrating that inhibition of ERK-1/2 signaling sensitizes cells to
chemotoxic insult supports this hypothesis (70). This notion is important in the context of ALD,
where cells can become sensitized early in the progression of a chronic disease where
subsequent toxic insults are likely. Although others have suggested an association between 4-
HNE and an increase in ERK-1/2 activity in immortalized cell lines (32,71), the concurrent
discovery that cell lines possess vastly different metabolic dispositions and sensitivities toward
4-HNE when compared with their primary counterparts, even when derived from cells of
normal origin (72), makes them suspect in the context of in vivo relevance and further highlights
potential cell-specific effects of reactive aldehydes. In addition to aberrations in normal ERK-
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associated homeostasis, inhibition of the ERK-1/2 pathway also implicates chronic ethanol
exposure in alterations of normal hepatic gene transcription (43,44).
Previous research has established the role of ERK-1/2 in mediating transcriptional gene
regulation through the ERK-ELK-AP-1 signal transduction pathway (42-44). These published
reports indicate that ERK-1/2 activity is responsible for the activation of the transcription factor
ELK-1, and subsequently the AP-1 component c-Fos, and to a lesser extent c-Jun. Our research
shows that ethanol-induced inhibition of ERK-1/2 results in the suppression of constitutive
ELK-1 phosphorylation that is independent of changes in nuclear ELK-1 protein levels.
Similarly, primary cells challenged with physiologic levels of 4-HNE demonstrate a
concentration-dependent loss of constitutive ERK-1/2 phosphorylation, activity toward
ELK-1, and nuclear localization resulting in a concentration-dependent suppression of nuclear
ELK-1 phosphorylation that is indicative of 4-HNE modulation of normal hepatocyte gene
expression. Activation of AP-1 through the upstream ERK-ELK kinase mediators results in
gene expression associated with cell homeostasis, proliferation, and cell survival (42,53,58).
Indeed, much effort has been expended to identify inhibitors of ERK-1/2 in cancerous cells for
use as novel chemotherapeutic agents (53,70) that negatively impact cell proliferation and/or
induce apoptosis. In light of previous experimental data that demonstrate the ethanol-driven
inhibition and/or delay of hepatic regeneration following surgical and chemical liver damage
(45,46), this study implicates the involvement of ethanol-induced lipid peroxidation and the
subsequent inhibition of the proliferative/pro-survival ERK-1/2 signaling pathway by 4-HNE
in this phenomenon. This hypothesis is substantiated by the data presented here, showing a
loss of nuclear ERK-1/2 in vivo and in primary hepatocytes and the 4-HNE-mediated decrease
of ERK-1/2 activity and ELK-1 phosphorylation.
Under conditions of homeostatic balance, divergent MAPK pathways control the juxtaposed
expression of pro-apoptotic and anti-apoptotic transcription factors such as c-Fos and c-Jun
(58,73,74). Here we have shown that the repeated chemical insults associated with ALD result
in the 4-HNE-mediated impairment of constitutive ERK-1/2 signaling through ELK-1 in
hepatocytes (Fig. 7, dotted arrows). This event could lead to the loss of constitutive AP-1
transcriptional activity, resulting in a decrease in proliferative/anti-apoptotic gene expression
(Fig. 7, dashed arrows). Although the liver is typically considered a quiescent organ, the
average turnover rate of hepatocytes is know to be ~300 days. Given that there are roughly
300–600 million hepatocytes in the rat liver (data based on current hepatocyte isolation
protocols used in this study), statistically there should be an approximate daily turnover of 1–
2 million cells. Consequently, hepatocyte nuclear extracts from the animals used in this study
were evaluated for changes in PCNA levels, which demonstrate a significant decrease in PCNA
staining in ethanol liver extracts when compared with controls (Fig. 8A; n = 12, p > 0.005).
Preliminary investigations into the role of 4-HNE in the decreased hepatocyte proliferation
observed following chronic ethanol ingestion indicates that increasing concentrations of
exogenous 4-HNE added to primary control rat hepatocytes decrease PCNA levels and
therefore basal hepatocyte proliferation. Although these data are preliminary and warrant
further investigation, these observations suggest that decreases in constitutive levels of
hepatocyte proliferation following chronic ethanol intake may also be mediated by the effects
of 4-HNE on ERK-1/2 signaling shown in the studies presented here. Additionally, research
by Parola and co-workers (26,31) demonstrates the ability of 4-HNE to increase the activity
of the MAPK c-Jun amino-terminal kinase (JNK), a known pro-apoptotic pathway, which
could further affect the apoptotic balance in hepatocytes. Although studies by Parola and co-
workers (26,31) suggest that 4-HNE has no effect on ERK-1/2 activity in hepatic stellate cell
cultures, recent evidence indicates that chemical inhibitors of ERK-1/2 are capable of
concurrently inducing the JNK signaling pathway, disrupting the apoptotic balance in favor of
programmed cell death (53). Additional evidence indicates the ability of 4-HNE to induce
apoptosis in several other cell types (75-79). Although major functional diversity exists among
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the MAPK family members, the highly conserved nature of MAPK sequences (43,44) suggest
that numerous 4-HNE target residues likely exist for all family members. It is therefore
probable, under conditions of chronic ethanol insult and repeated situations of lipid
peroxidation, that the production of 4-HNE simultaneously decreases the pro-survival ERK-1/2
signaling pathway while increasing the pro-apoptotic JNK signaling pathway through
aldehyde-protein adduct formation at different functionally sensitive residues. Although this
seems a likely hypothesis, terminal dUTP nick-end labeling staining of liver sections from
control and ethanol-treated animals used in this study revealed no change in apoptotic incidence
(data not shown; TACS TdT 3′,3′-diaminobenzidine kit, R & D Systems), indicating that the
inhibition of ERK-1/2 signaling observed here effects homeostasis and proliferation without
affecting the apoptotic balance of the hepatocyte.
Interestingly, the treatment of primary hepatocytes with concentrations of 4-HNE up to 100
μM resulted in a substantial yet incomplete inhibition of constitutive ERK-1/2 phosphorylation.
At the origin of lipid peroxidation within membranes, cellular concentrations of 4-HNE have
been estimated to exceed 1 mM (54). Subsequent experiments have shown that treatment with
1 mM 4-HNE results in the complete ablation of ERK-1/2 phosphorylation in primary
hepatocyte cultures (data not shown). However, this concentration of aldehyde was determined
to be significantly cytotoxic under these conditions and therefore outside the scope of this
investigation. Additionally, it is conceivable that other toxic mediators associated with ethanol-
induced lipid peroxidation elicit synergistic effects resulting in the complete inhibition of this
pathway, as seen in vivo. Previous studies supporting this concept show that the ethanol
metabolite acetaldehyde enhances the covalent modification of cellular molecules by the lipid
peroxidation product malondialdehyde (68,80,81). It must also be acknowledged that the loss
of ERK-1/2 phosphorylation observed in this study may be confounded by 4-HNE modification
and inhibition of upstream kinases (i.e. MEK-1/2) or stimulation of MAPK phosphatases,
although a significant accumulation of inactive nuclear ERK-1/2 would be anticipated for this
latter explanation as reported elsewhere (82). Ultimately, these novel findings illustrated in
Fig. 7 suggest that 4-HNE is capable of modulating the homeostatic, proliferative, and pro-
survival ERK-1/2 signal transduction pathway in hepatocytes, resulting in the loss of signaling
through ELK-1 and potentially through the family of AP-1 transcription factors.
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FIGURE 1. Primary amino acid sequences of ERK-2 protein from human and common
experimental animals showing greater than 96% homology across the species
The primary sequences of ERK-2 from H. sapiens (top row), M. musculus (2nd row), R.
norvegicus (3rd row), and X. laevis (4th row) were obtained from NCBI (P28482, P63085,
P63086, and P26696, respectively) and aligned to the human primary sequence. Highlighted
regions of these sequences indicate homologous sequences across the species that are greater
than 98% identical to human for mouse and rat and greater than 96% identical to human for
Xenopus, indicating that experimental alternatives to human are appropriate for studies focused
on the extracellular signal-regulated kinase pathway.
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FIGURE 2. Ethanol-induced differences in rat liver pathology and the lobular and cellular
localization of 4-HNE-protein adducts and ERK-1/2
Representative serial sections of rat liver from animals fed a control liquid diet or a diet
containing 35% ethanol-derived calories for 60 days. A, hematoxylin and eosin staining of a
control liver section showing normal hepatolobular architecture with chords of hepatocytes
radiating out from the central vein (CV) to the portal triad (PV), with clear linear sinuses
between the chords (×10 magnification). B, hematoxylin and eosin staining of a liver section
from an ethanol-treated rat demonstrating the loss of normal hepatic architecture and the
accumulation of lipid (steatosis) within hepatocytes surrounding the central vein (×10
magnification). B2, ×80 magnification of the ethanol-treated liver section from B, showing the
cytosolic accumulation of lipid within hepatocytes (microvesicular = small arrowheads,
macrovesicular = large arrowheads). C, control liver section stained against 4-HNE-modified
proteins that demonstrate a faint, pan-lobular positive staining (×10 magnification). D, 4-HNE-
Sampey et al. Page 17













adduct staining indicating the ethanol-induced accumulation of protein adducts within the
central lobular and mid-zonal regions and clearly absent in areas proximal to the central veins
(×10 magnification). D2, ×80 magnification of D indicating the cytosolic accumulation of 4-
HNE-protein adducts and the relative lack of positive nuclear staining (hematoxylin
counterstain). E, control liver section stained against total ERK-1/2, indicating a diffuse pan-
lobular staining (×10 magnification). F, total ERK-1/2 staining indicating the ethanol-induced
accumulation of ERK protein within the central lobular and mid-zonal regions and clearly
absent in areas proximal to the central veins, similar to observations made for 4-HNE-adduct
accumulation in D (×10 magnification). F2, ×80 magnification of F demonstrating the cytosolic
accumulation of ERK-1/2 and the distinct lack of positive nuclear staining in most cells (27/
×40 field compared with 63/×40 field in control liver sections), also similar to observations
made for the cellular accumulation of 4-HNE adducts in D2. G, control liver section stained
against phospho-ERK-1/2, showing distinct positive staining nuclei (64/×40 field) throughout
the tissue and moderate cytosolic staining (×40 magnification). H, phospho-Erk-1/2 staining
indicating the ethanol-induced loss of positive nuclear staining (25/×40 field) with moderate
cytosolic staining absent in the midzonal region (center of image, ×40 magnification). I, control
liver section stained against total ELK-1 showing distinct positive nuclear staining (51/×40
field) throughout the tissue and diffuse cytosolic staining (×40 magnification). J, total ELK-1
staining of liver from an ethanol-treated animal. Although there is obvious loss of structural
organization within the tissue, the number of positive staining nuclei per ×40 field is maintained
(52/×40 field) when compared with control I. K, control liver section stained against
phosphorylated ELK-1 demonstrating distinct positive nuclei (47/×40 field) throughout the
tissue and diffuse cytosolic staining (×40 magnification). L, phospho-ELK-1 staining of
ethanol-treated animal liver showing a significant loss of positive staining nuclei per ×40 field
(18/×40 field) when compared with control (×40 magnification).
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FIGURE 3. Ethanol induces increased 4-HNE-ERK-1/2 adduct formation, which is inversely
correlated with the loss of constitutive ERK-1/2 phosphorylation
Immunoblot analysis using hepatocytes isolated from animals consuming control and ethanol-
containing diets for 45 days is shown. A, immunoblot analysis of hepatocyte total ERK-1/2
concentrations, showing no effect of ethanol when compared with control (stripped blots
reprobed for B-actin shows equal loading). B, immunoblot analysis of phosphorylated ERK-1/2
indicates that chronic ethanol ingestion ablates constitutive ERK-1/2 phosphorylation (stripped
blots reprobed for B-actin shows equal loading). C, immunoblot and corresponding
densitometry demonstrating chronic ethanol administration results in the significant increase
in 4-HNE-ERK-2 adduct concentration as indicated by immunoprecipitated ERK-1/2, probed
for 4-HNE-protein adducts. Corresponding densitometry analysis normalized to the total
ERK-2 immunoprecipitated (D) indicates a significantly elevated level of adduct
concentrations in ethanol-treated animals (p < 0.0042). D, total ERK-2 protein concentrations
demonstrated by Coomassie Blue staining of immunoprecipitated ERK-2 and corresponding
densitometry using hepatocyte lysates from control and ethanol-treated animals indicating
increased concentrations of ERK-2 purified from control samples when compared with
ethanol-treated samples (p < 0.05). (*, p < 0.05, n = 4.)
Sampey et al. Page 19













FIGURE 4. Sub-cytotoxic 4-HNE treatment of primary rat hepatocyte cultures results in a
concentration-dependent decrease in ERK-1/2 phosphorylation and activity that is inversely
correlated with the increase in 4-HNE-ERK-1/2 adduct concentration
The cytotoxicity of 4-HNE after 4 h of treatment on primary rat hepatocytes was determined
over a range of physiologic concentrations. A, cytotoxicity shown as the ratio of release LDH
activity over total cellular LDH activity, indicating a lack of cytotoxicity from 0 to 100 μM 4-
HNE. These sub-cytotoxic concentrations were used for subsequent primary culture
experiments. B, immunoblot indicating a concentration-dependent decrease in ERK-1/2
phosphorylation when compared with constitutive control levels (lane 1, 0 μM 4-HNE) (B-actin
reprobe of stripped blots confirms equal loading). C, immunoblot analysis of total ERK-1/2
protein indicating no change with increasing concentrations of 4-HNE treatment (B-actin
reprobe of stripped blots indicates equal loading). D, ERK-1/2 activity assay demonstrating
the concentration-dependent suppression of immunoprecipitated ERK-1/2 collected from
primary cultures exposed to increasing levels of 4-HNE to phosphorylate the ELK-1 substrate.
D, inset, active, phosphorylated IP-ERK-1/2 from control hepatocytes is not affected by
increasing concentrations of 4-HNE, indicating 4-HNE-mediated effects on ERK-1/2 result
from interactions with the inactive, unphosphorylated ERK monomers. E, Western blot
analysis of activity assay components probed for 4-HNE-protein adducts indicating an inverse
correlation between ERK-1/2 phosphorylation and activity and the concentration-dependent
increase in 4-HNE-adducted ERK-1/2 levels in primary hepatocytes. (*, p < 0.05, n = 9.)
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FIGURE 5. Sub-cytotoxic 4-HNE treatment of primary rat hepatocyte cultures results in a
concentration-dependent decrease in the in situ activity of ERK-1/2 that correlates with aldehyde-
dependent decreases in phosphorylated and total ERK-1/2 in the nucleus
A, Western blot analysis of nuclear phosphorylated ERK-1/2 shows a loss of positive staining
with increasing 4-HNE concentrations used to treat primary hepatocytes. B, unlike the analysis
of total cell lysates, analysis of total nuclear ERK-1/2 indicates that the loss of nuclear phospho-
ERK-1/2 results from the 4-HNE-mediated decrease in total ERK-1/2 protein concentrations,
a change indicative of cytosolic modification and inhibition. C, immunoblot analysis of total
hepatocyte lysates probed against the ERK-1/2 substrate, ELK-1, shows no effect of 4-HNE
on total nuclear ELK-1 concentrations. D, immunoblot analysis and densitometry of nuclear
phosphorylated ELK-1 demonstrating a concentration-dependent inhibition of ERK-1/2
activity in situ as shown by a loss of phosphorylated substrate with increasing 4-HNE
concentrations. (*, p < 0.05, n = 5.)
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FIGURE 6. Pathologic molar ratios of 4-HNE to unphosphorylated ERK-2 protein result in the
accumulation of aldehyde-monomer adducts similar to observations in vivo and in primary culture
A, immunoblot analysis of inactive ERK-2 protein incubated with increasing physiologic
concentrations of 4-HNE and probed for 4-HNE-protein adducts shows the formation of the
4-HNE-ERK-2 monomer adducts as the predominant adducted species (lower, 42-kDa bands).
At the highest concentration (100 μM), 4-HNE adduction of unphosphorylated ERK-2 results
in chemical cross-linking, as demonstrated by the partial shift from 42 to 82 and 126 kDa
(arrowheads) for 4-HNE-adduct-positive staining bands. B, immunoblot analysis of the blot
in A, when stripped and reprobed for total ERK-1/2 protein, that shows a partial loss of positive
signal that correlates with the cross-linking of ERK-2 monomers at 100 μM 4-HNE. These data
suggest that two distinct adduct species exist, where only the 100 μM 4-HNE treatment results
in cross-linked adducts that preclude the recognition of the epitope by the total ERK-1/2
antibody.
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FIGURE 7. Alterations to ERK-1/2 signaling pathway imposed by 4-HNE
In normal non-ethanol-exposed and non-aldehyde-exposed hepatocytes, upstream kinase
events (solid arrows) cascade down through ERK-1/2 to phosphorylate and activate this
signaling intermediate, resulting in the active transport of ERK-1/2 into the nucleus where
phosphorylation of downstream ELK-1 and subsequently AP-1 (c-Fos, and to a lesser extent
c-Jun) result in transcriptional activity. During ethanol-induced lipid peroxidation, 4-HNE
forms covalent adducts with inactive ERK-1/2 in the cytosol, preventing its phosphorylation,
activation, and nuclear translocation, which results in the loss of downstream ELK-1 activity
(dotted arrows). The 4-HNE-mediated inactivation of ERK-1/2 and the subsequent loss of
ELK-1 activity could potentially result in the loss of normal transcriptional activity through
the c-Fos and c-Jun AP-1 transcription factors associated with proliferation, cell survival, and
homeostasis (dashed arrows).
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FIGURE 8. Ethanol and 4-HNE suppress basal hepatocyte proliferation
A, representative immunoblot analysis and corresponding densitometry analysis of PCNA
using nuclear extracts of hepatocytes isolated from control animals (1st to 4th lanes, left to
right) and animals consuming ethanol for 45 days (5th to 8th lanes, left to right) showing a
36.7% ethanol-dependent decrease in constitutive cell proliferation when compared with
control levels (n = 12, p < 0.005). B, preliminary data showing an immunoblot for PCNA using
nuclear extracts from primary hepatocytes treated with increasing concentrations of 4-HNE,
suggesting a concentration-dependent decrease in cell proliferation with increasing 4-HNE.
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TABLE 1
Conservation of nucleophilic amino acids (aa) preferentially reactive toward 4-HNE
Primary amino acid sequences of ERK-2 from human, M. musculus, R. norvegicus, and X. laevis were examined
to determine the number of potential residues reactive toward 4-HNE, namely cysteine, histidine, and lysine, and
to establish that these sites are conserved across experimental species when compared with the human sequence.
Despite subtle differences in their primary sequences, all species variants of ERK-2 possessed the 7 cysteine, 13
histidine, and 23 lysine residues that were observed within the human, primary ERK-2 sequence, indicating that
the mechanistic modification of nucleophilic sites by 4-HNE would act through conserved residues.
Cysteine residues Histidine residues Lysine residues Total potential targets
Human 7 13 23 43/360 aa
M. musculus 7 13 23 43/358 aa
R. norvegicus 7 13 23 43/358 aa
X. laevis 8 14 23 45/361 aa
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